Compare Amphastar Pharmaceuticals Inc (AMPH) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Prospect Capital Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Prospect Capital Corporation trades at $2.25 (market cap $1.13B). The key difference: Prospect Capital Corporation is the larger of the two by market cap, and Prospect Capital Corporation pays a 22.17% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PSEC | |
|---|---|---|
Market Cap | $826.08M | $1.13B |
Sector | Health | Financials |
52-Week High | $30.81 | $3.47 |
52-Week Low | $16.87 | $2.15 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 22.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
PSEC trades at $2.26, up 2.26% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.38 and has beaten EPS estimates for three consecutive quarters. Recent news includes a new investment in ShipOffers and the sale of Valley Electric generating $328 million. Dividend payments continue at $0.04-$0.05 monthly, supporting income appeal despite negative revenue and net income in 2025.
Outlook remains cautious due to persistent negative profitability and revenue volatility, though deep discount to NAV and high yield may attract income investors. Key risks include declining NAV, portfolio quality concerns, and analyst skepticism. Upside depends on stabilization of investment income and successful execution of senior lending strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
